243641-09-0

Upstream product

• 6547-53-1 2-[4-(benzyloxy)benzyl]acetic acid 
• 6638-79-5 N,O-dimethylhydroxylamine*hydrochloride 
• 1117-97-1 N,0-dimethylhydroxylamine 
• 58609-13-5 4-(benzyloxy)phenylacetic acid benzyl ester 
• 156-38-7 4-hydroxyphenylacetate 

Downstream Products

• 735266-30-5 2-[4-(Benzyloxy)phenyl]-1-(6-methoxy-3-pyridinyl)ethanone 
• 1331775-09-7 1-(4-benzyloxyphenyl)hexan-2-one 
• 1331775-36-0 1-(4-benzyloxyphenyl)pentan-2-one 
• 1331775-10-0 3-(4-benzyloxyphenyl)-2-hydroxy-4-oxooctanoic acid ethyl ester 
• 1331775-11-1 5-(4-benzyloxyphenyl)-6-butyl-2H-pyridazin-3-one 
• 1331775-12-2 4-(4-benzyloxyphenyl)-3-butyl-6-chloropyridazine 
• 1331775-15-5 4-(4-benzyloxyphenyl)-3-butyl-6-(1-methylpiperidin-4-yloxy) pyridazine 
• 1331775-16-6 4-[5-(4-benzyloxyphenyl)-6-butylpyridazin-3-yloxymethyl]piperidine-1-carboxylic acid tert-butyl ester 
• 1331773-95-5 4-(4-benzyloxyphenyl)-3-butyl-6-(1-methylpiperidin-4-ylmethoxy)pyridazine 
• 1331775-19-9 {2-[5-(4-benzyloxyphenyl)-6-butylpyridazin-3-yloxy]-ethyl} diethylamine 
• 1331775-20-2 {3-[5-(4-benzyloxyphenyl)-6-butylpyridazin-3-yloxy]-propyl} diethylamine 
• 1331775-21-3 4-(4-benzyloxyphenyl)-3-butyl-6-(3-piperidin-1-ylpropoxy) pyridazine 
• 1331775-40-6 4-(4-benzyloxyphenyl)-6-(1-methylpiperidin-4-yloxy)-3-propylpyridazine 
• 1331775-37-1 3-(4-benzyloxyphenyl)-2-hydroxy-4-oxoheptanoic acid ethyl ester 

Relevant academic research and scientific papers

Synthesis and structure-activity relationships of tri-substituted thiazoles as RAGE antagonists for the treatment of Alzheimer's disease

A series of thiazole derivatives were designed, and prepared to develop RAGE antagonist for the treatment of Alzheimer's disease (AD). SAR studies were performed to optimize inhibitory activity on Aβ-RAGE binding. SAR studies showed that introducing an amino group at part A was essential for inhibitory activity on Aβ-RAGE binding. Compounds selected from Aβ-RAGE binding screening displayed inhibitory activity on Aβ transport across BBB. They also showed inhibitory activity against Aβ-induced NF-κB activation. These results indicated that our derivatives had a potential as therapeutic agent for the treatment of AD.

Efficient synthesis of 1-Benzyloxyphenyl-3-phenylacetones

1-[(Benzyloxy)phenyl]-3-phenylacetones 1a-c have been conveniently synthesized by acylation of the PhCH2Li-DABCO complex with their respective N-methyl O-methyl hydroxamates 5a-c. In four steps, ketones 1a-c having ortho-, meta- and para-benzyloxy substituents were obtained in 42-51% overall yields from commercially available 2-(hydroxyphenyl)acetic acids.